Drug Profile
Cladribine - Johnson and Johnson/Merck Serono
Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Mavenclad; Movectro; Mylinax; PRMavenclad; RWJ-26251Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Scripps Clinic
- Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
- Class Antineoplastics; Antipsoriatics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Skin disorder therapies; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
- No development reported Psoriasis; Transplant rejection
Most Recent Events
- 23 May 2023 University of Washington in collaboration with AbbVie suspends phase I trial in phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA due to pending protocol amendment (IV) (NCT04797767)
- 01 Nov 2022 Merck KGaA completes a phase I trial for Multiple Sclerosis in Germany and Poland (PO) (NCT03745144)
- 28 Feb 2022 Adverse events data from a phase III CLARITY trial in Multiple sclerosis released by Merck